To address this issue, we previously developed a method to optimize the pharmacokinetics of [211At]1, namely, accumulation of [211At]1 in the tumor, followed by administration of an albumin-binding inhibitor to accelerate the [211At]1 clearance [31]. The gene discussed is ALB; the disease is neoplasm.